Bioventix plc was founded in 2003 as a biotechnology business specialising in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics. Our antibody technology, laboratory and some of our team of scientists have been based at the same location in Farnham, Surrey, UK since the 1990s.
Focusing on the areas of clinical diagnostics and drugs of abuse testing the Company’s strategy is to identify new or existing commercial assays for which there is or may be a need for improved antibodies. We aim to provide customers with high quality SMAs that address the shortcomings of other antibodies. The high-affinity antibodies created at Bioventix have advantages over conventional rodent monoclonal antibodies where the target is present at low concentration, or where the target is a short peptide sequence or where the target is a small molecule or drug. In many assay formats, the use of high-affinity SMAs confers improved assay sensitivity and precision.
Bioventix has successfully developed SMAs to targets where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent and supplies antibodies to almost all of the global multinational immunodiagnostics companies.
The company was admitted to trade on the Alternative Investment Market (AIM) on the London Stock Exchange in April 2014. Since then the company has consistently delivered high levels of growth in both revenue and profitability resulting in excellent value creation for our shareholders.